Ariad Pharmaceuticals (NASDAQ: ARIA ) Q2 2014 Earnings Call August 06, 2014 8:30 am ET Executives Maria E. Cantor - Senior Vice President of Corporate Affairs
Ariad Pharmaceuticals (NASDAQ: ARIA ) Q2 results: Total Revenues: $14.0M (+82.3%), Net Product Sales: $12.1M (+82.3%); Operating Expenses
The following audio is from a conference call that will begin on August 06, 2014 at 08:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
ARIAD Pharmaceuticals (NASDAQ: ARIA ): Q2 EPS of -$0.30 misses by $0.01 . Revenue of $12.1M (-13.6% Y/Y) misses by $1.77M . Press Release 1 comment!
Ariad Pharmaceuticals ( ARIA +1.2% ) grants Medison Pharma Ltd exclusive rights to commercialize Iclusig ( ponatinib ) in Israel. Under the terms of the
Nov 1 (Reuters) - Ariad Pharmaceuticals Inc adopted a shareholder rights plan to protect its tax credits, a day after sales of its flagship drug Iclusig were suspended due to safety concerns...
(Reuters) - Ariad Pharmaceuticals ' shares fell 3 percent on Wednesday morning after a U.S. Food and Drug Administration panel did not recommend the company's experimental cancer candidate.